1441TiP An open-label, phase Ib trial to assess the safety and efficacy of SIRPα monoclonal antibody BI 770371 in combination with pembrolizumab with or without cetuximab compared with pembrolizumab monotherapy for the first-line treatment of patients with head and neck squamous cell carcinoma (NCT06806852) - Laban, S.; Osinowo, S.; Hu, C.; Tosiek, M.; Pronk, L.C. (Annals of Oncology, 2025)